Patents Assigned to Scinopharm Taiwan, Ltd.
  • Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
    Patent number: 8846953
    Abstract: The present invention provides for synthetic processes for the making of substituted 3-((pyrrol-2-yl)methylene)-2-pyrrolones, including sunitinib. The present invention also provides for a process of crystallizing substantially pure sunitinib L-malate.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: September 30, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian P. Henschke, Yung-Fa Chen
  • Real-time monitor solid phase peptide synthesis by mass spectrometry
    Patent number: 8835179
    Abstract: Provided are systems, apparatus, materials and methods for directly monitoring products and intermediates of solid phase chemical synthesis such as solid phase peptide synthesis.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: September 16, 2014
    Assignees: ScinoPharm Taiwan, Ltd., National Sun Yat-Sen University
    Inventors: Li-Chiao Chang, Jentaie Shiea, Yi-Tzu Cho
  • PROCESS FOR IXABEPILONE, AND INTERMEDIATES THEREOF
    Publication number: 20140256952
    Abstract: The present invention relates to a novel process of making ixabepilone, ixabepilone derivatives and analogues, and intermediates thereof.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 11, 2014
    Applicant: ScinoPharm Taiwan, Ltd.
    Inventors: Yue Chen, Tsung Yu Hsiao, Julian P. Henschke
  • Inhibition-based high-throughput screen strategy for cell clones
    Patent number: 8765370
    Abstract: A method for screening cells with high level expression of a target protein is disclosed. The method includes introducing into a plurality of host cells a DNA construct that encodes both a target protein and an inhibitor to an endogenous selectable marker in the host cells, screening host cells harboring the DNA construct for the expression of the endogenous selectable marker, and isolating cells with reduced expression of the selectable marker. Also disclosed is a DNA construct configured to express both the target protein and the inhibitor inside the host cell.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: July 1, 2014
    Assignee: Scinopharm Taiwan, Ltd
    Inventors: Wei-Kuang Liu, Min-Pey Ding
  • Process for the preparation and purification of topiramate
    Patent number: 8748594
    Abstract: A process for the preparation of topiramate in an one pot reaction comprises the following steps: A) reacting 2,3:4,5-bis-O-{1-methylethylidene)-?-D-fructopyranose with sulfurylchloride in xylene in the presence of an organic or inorganic base to form 2,3:4,5-bis-O-(1-methylethylidene)-?-D-fructopyranose sulfuryl chloride, B) adding a second organic solvent to the mixture obtained in step A) C) reacting the mixture obtained in step B) with ammonia to form topiramate.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 10, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Lung-Hu Wang, Chun-Teng Huang
  • Process for the preparation of prostaglandin analogues
    Patent number: 8742143
    Abstract: A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8?): to the prostaglandin analogue, wherein R3 represents hydrogen or a hydroxyl protecting group.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: June 3, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian P. Henschke, Yuanlian Liu, Yung-Fa Chen, Dechao Meng, Ting Sun
  • Crystalline forms of cabazitaxel
    Patent number: 8735611
    Abstract: The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8b, C9 and C9p.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: May 27, 2014
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, TsungYu Hsiao, MengFen Ho, YuanChang Huang
  • Process for cabazitaxel, and intermediates thereof
    Patent number: 8722900
    Abstract: The present invention relates to processes for making cabazitaxel, cabazitaxel analogues and intermediates thereof. The invention provides novel compounds useful in the synthesis of cabazitaxel.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: May 13, 2014
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: TsungYu Hsiao, Julian Paul Henschke, HsinChang Tseng
  • Process for the Preparation of ß-C-Aryl Glucosides
    Publication number: 20140128595
    Abstract: The present invention provides processes for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors.
    Type: Application
    Filed: November 7, 2012
    Publication date: May 8, 2014
    Applicant: ScinoPharm Taiwan, LTD.
    Inventors: Julian Paul Henschke, Chen-Wei Lin, Ping-Yu Wu, Chi-Nung Hsiao, Jyh-Hsiung Liao, Tsung-Yu Hsiao
  • Process and intermediates for preparing lapatinib
    Patent number: 8710221
    Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: April 29, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Yung-Fa Chen, Julian Paul Henschke, Xiaoheng Zhang, YiJing Chen, ChunFang Xu, Yong Mu
  • CRYSTALLINE FORMS OF CABAZITAXEL
    Publication number: 20140045926
    Abstract: The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8b, C9 and C9p.
    Type: Application
    Filed: August 12, 2013
    Publication date: February 13, 2014
    Applicant: ScinoPharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, TsungYu Hsiao, MengFen Ho, YuanChang Huang
  • Preparation of 2-chloro-9-(2?-deoxy-2?-fluoro-?-D-arabinofuranosyl)-adenine
    Patent number: 8648188
    Abstract: A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group, OR6 is a leaving group, with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: February 11, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Lijun Mei, Yung-Fa Chen
  • Methods for Chemical Equivalence in characterizing of complex molecules
    Patent number: 8643274
    Abstract: The present invention provides for a method of characterizing and classifying a sample containing a complex molecule, such as a peptide or polypeptide mixture, protein, protein mixture, biologic and biosimilar by using physical analysis, such as mass spectrometry, and statistic methods.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: February 4, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Hardy Chan, Jentaie Shiea
  • Vector for inhibition-based high-throughput screen strategy
    Patent number: 8642327
    Abstract: A method for screening cells with high level expression of a target protein is disclosed. The method includes introducing into a plurality of host cells a DNA construct that encodes both a target protein and an inhibitor to an endogenous selectable marker in the host cells, screening host cells harboring the DNA construct for the expression of the endogenous selectable marker, and isolating cells with reduced expression of the selectable marker. Also disclosed is a DNA construct configured to express both the target protein and the inhibitor inside the host cell.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: February 4, 2014
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Wei-Kuang Liu, Min-Pey Ding
  • PROCESS AND INTERMEDIATES FOR PREPARING LAPATINIB
    Publication number: 20140024829
    Abstract: A compound of formula (X): which can be used as an intermediate to make lapatinib or its pharmaceutically acceptable salt.
    Type: Application
    Filed: September 18, 2013
    Publication date: January 23, 2014
    Applicant: SCINOPHARM TAIWAN, LTD.
    Inventors: Yung-Fa CHEN, Julian Paul HENSCHKE, Xiaoheng ZHANG, YiJing CHEN, ChunFang XU, Yong MU
  • Synthesis of decitabine
    Patent number: 8586729
    Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: November 19, 2013
    Assignee: Scinopharm Taiwan Ltd.
    Inventors: Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei
  • Crystalline forms of cabazitaxel
    Patent number: 8575373
    Abstract: The present invention provides crystalline forms, including an anhydrate form, of cabazitaxel and processes for the preparation of these forms, designated as Forms C1, C2, C3, C4, C5, C6, C7, C8, C8b, C9 and C9p.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: November 5, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Julian Paul Henschke, TsungYu Hsiao, MengFen Ho, YuanChang Huang
  • Process and intermediates for preparing lapatinib
    Patent number: 8563719
    Abstract: The present invention provides a process for making lapatinib and its pharmaceutically acceptable salt by use of new intermediates. A new process for obtaining a pharmaceutical form of lapatinib ditosylate monohydrate is also provided.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: October 22, 2013
    Assignee: Scinopharm Taiwan, Ltd.
    Inventors: Yung-Fa Chen, Julian Paul Henschke, Yuanlian Liu, Guodong Chu, Xiaoheng Zhang
  • CRYSTALLINE AND NON-CRYSTALLINE FORMS OF SGLT2 INHIBITORS
    Publication number: 20130237487
    Abstract: The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 12, 2013
    Applicant: Scinopharm Taiwan, LTD.
    Inventors: Julian Paul Henschke, Meng-Fen Ho, Shu-Ping Chen, Yung-Fa Chen
  • Process for the Preparation of Prostaglandin Analogues
    Publication number: 20130211128
    Abstract: A process for preparing a prostaglandin analogue comprising a step of converting a compound of formula (8?): to the prostaglandin analogue, wherein R3 represents hydrogen or a hydroxyl protecting group.
    Type: Application
    Filed: March 27, 2013
    Publication date: August 15, 2013
    Applicant: SCINOPHARM TAIWAN LTD.
    Inventors: Julian P. HENSCHKE, Yuanlian LIU, Yung-Fa CHEN, Dechao MENG, Ting SUN